Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights
Rhea-AI Summary
Arcadia Biosciences (Nasdaq: RKDA) reported first quarter 2026 results. Zola coconut water unit volumes rose 18% year-over-year, supported by a price increase, though total revenues declined 8% to $1.1 million.
Total operating expenses climbed to $1.9 million, while SG&A reached the lowest level in company history. Net loss attributable to common stockholders was $4.4 million, versus $2.6 million net income a year earlier, impacted by a $2.9 million warrant inducement loss. Arcadia also received approximately $2.1 million in gross proceeds from exercises of preferred investment options.
Positive
- Zola coconut water unit volumes up 18% year-over-year
- Total revenues of $1.1 million in Q1 2026
- SG&A expenses at lowest level in company’s public history
- SG&A decreased by $559,000 year-over-year in Q1 2026
- Gross proceeds of approximately $2.1 million from option exercises
Negative
- Total revenues decreased by $100,000 (8%) year-over-year
- Total operating expenses increased by $1.2 million year-over-year
- Net result swung to $4.4 million loss from $2.6 million income
- Q1 2026 warrant inducement offer generated a $2.9 million loss
- Additional other loss of $1.5 million in Q1 2026
- Loss from continuing operations of $779,000 versus $530,000 income
News Market Reaction – RKDA
In the May 15 session, RKDA declined 10.69%, reflecting a significant negative market reaction. Argus tracked a peak move of +30.8% during that session. Argus tracked a trough of -9.6% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Q4/FY 2025 earnings | Neutral | -3.3% | Reported Q4/FY25 results, Zola growth, and Roosevelt deal termination. |
| Nov 07 | Q3 2025 earnings | Neutral | -2.2% | Mixed Q3 with Zola growth, strong margins, and large credit loss. |
| Aug 14 | Q2 2025 earnings | Neutral | +5.6% | Q2 revenue growth offset by major credit loss and net loss swing. |
| May 08 | Q1 2025 earnings | Positive | -0.2% | Strong Q1 2025, revenue up 22% and return to net income. |
| Mar 20 | Q4/FY 2024 earnings | Neutral | -4.5% | Strong 2024 Zola growth and asset sales but continued net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have often been operationally mixed, with modest average price moves and one notable instance where strong results were followed by a small negative reaction.
Recent earnings updates highlight Arcadia’s transition to the Zola coconut water business and balance-sheet reshaping. Prior quarters featured strong Zola growth and margin stability but also sizable credit losses, contingent liability adjustments, and the terminated Roosevelt Resources deal. Net results have swung between income and loss, with 24-hour stock reactions around earnings averaging a small decline of -0.94%. This Q1 2026 report continues the focus on Zola growth alongside volatile bottom-line items.
Key Terms
revenue reserve financial
contingent consideration liability financial
warrant inducement offer transaction financial
Form 8-K regulatory
Form 10-Q regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
-- Zola® volumes increase
-- SG&A at lowest level in Arcadia’s history --
DALLAS, May 14, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the first quarter of 2026.
“We are very pleased with our performance during the first quarter of 2026,” said T.J. Schaefer, CEO of Arcadia. “We were able to bring in gross proceeds of approximately
“Going forward, we continue to evaluate strategic alternatives but also remain focused on growing our Zola coconut water brand and are excited about the prospects of launching a new product that we expect to be on the shelves of many of our largest customers this fall,” Schaefer added.
| Arcadia Biosciences, Inc. Financial Snapshot (Unaudited) ($ in thousands) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | Favorable / (Unfavorable) | ||||||
| $ | % | |||||||
| Total revenues | 1,100 | 1,200 | (100) | ( | ||||
| Total operating expenses | 1,879 | 670 | (1,209) | ( | ||||
| (Loss) income from continuing operations | (779) | 530 | (1,309) | ( | ||||
| Net (loss) income attributable to common stockholders | (4,385) | 2,599 | (6,984) | ( | ||||
More detailed financial information is included in the company’s Report on Form 8-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), available in the Investors section of the company’s website under SEC Filings.
Revenues
Sales of Zola coconut water unit volumes increased
Operating Expenses
Total operating expenses increased by
Cost of revenues increased
Selling, general, and administrative expenses decreased by
Net Loss (Income) Attributable to Common Stockholders
Net loss attributable to common stockholders for the first quarter of 2026 was
About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products. For more information, visit www.arcadiabio.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations concerning the company and its products, including, but not limited to, statements relating to Zola products and sales, the company’s growth, cash position, operating costs, financial performance, evaluation of possible strategic alternatives and transactions, and the impact on shareholder value. Undue reliance should not be placed on any forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from the results anticipated by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2025 (the 2025 Form 10-K), and other filings that the company makes with the SEC. Forward-looking statements concerning anticipated future activities also assume that the company has sufficient funding to continue its operations and planned activities, which may not be the case. As described in greater detail in the 2025 Form 10-K and in the company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026, the company will require additional funding in the near future to continue its operations and planned activities. There are no assurances that required funding will be available at all or will be available in sufficient amounts or on reasonable terms. The company may seek to raise additional funds through equity or debt financings, through transactions involving its other assets, or through other transactions. Any sale of additional equity securities could result in dilution to company stockholders. Reported results should not be considered as an indication of future performance. Forward-looking statements made in this press release speak only as of the date hereof, and except as required by law, Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements or to reflect events or circumstances arising after the date of this press release.
Arcadia Biosciences Contact:
T.J. Schaefer
ir@arcadiabio.com
